Synthesis and Anti‐Proliferative Activity of a Triazole‐Fused Thymidine Analogue

The anti-breast cancer therapeutic potential of 1,2,3-triazole-containing hybrids

Breast cancer, as one of the most common invasive malignancies and the leading cause of cancer-related deaths in women globally, poses a significant challenge in the world health system. Substantial advances in diagnosis and treatment have significantly improved the survival rate of breast cancer patients, but the number of incidences and deaths of breast cancer are projected to increase by 40% and 50%, respectively, by 2040. Chemotherapy is one of the principal treatments for breast cancer therapy, but multidrug resistance and severe side effects remain the major obstacles to the success of treatment. Hence, there is a vital need to develop novel chemotherapeutic agents to combat this deadly disease. 1,2,3-Triazole, which can be effectively constructed by click chemistry, not only can serve as a linker to connect different anti-breast cancer pharmacophores but also is a valuable pharmacophore with anti-breast cancer potential and favorable properties such as hydrogen bonding, moderate dipole moment, and enhanced water solubility. Particularly, 1,2,3-triazole-containing hybrids have demonstrated promising in vitro and in vivo anti-breast cancer potential against both drug-sensitive and drug-resistant forms and possessed excellent selectivity by targeting different biological pathways associated with breast cancer, representing privileged scaffolds for the discovery of novel anti-breast cancer candidates. This review concentrates on the latest advancements of 1,2,3-triazole-containing hybrids with anti-breast cancer potential, including work published between 2020 and the present. The structure-activity relationships (SARs) and mechanisms of action are also reviewed to shed light on the development of more effective and multitargeted candidates.

1,2,3-Triazole derivatives with anti-breast cancer potential

Abstract:

Breast cancer is one of the most prevalent malignant diseases and one of the main mortality causes among women across the world. Despite advances in chemotherapy, drug resistance remains major clinical concerns, creating an urgent need to explore novel anti-breast cancer drugs. 1,2,3-Triazole is a privileged moiety, and its derivatives could inhibit cancer cell proliferation, and induce the cell cycle arrest and apoptosis. Accordingly, 1,2,3-triazole derivatives possess profound activity against various cancers including breast cancer. This review summarizes the latest progresses related to the anti-breast cancer potential of 1,2,3-triazole derivatives, covering articles published from January 2017 to December 2021. The mechanisms of action and structure-activity relationships (SARs) are also discussed for further rational design of more effective candidates.